Safety of therapeutics used in management of patent ductus arteriosus in preterm infants

Current Drug Safety

Volumn 10, Issue 2, 2015, Pages 106-112

  Oncel, Mehmet Yekta ^a   Erdeve, Omer ^b  

^a Zekai Tahir Burak Maternity Teaching Hospital   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Ibuprofen; Indomethacin; Paracetamol; Patent ductus arteriosus; Preterm infant; Safety

Indexed keywords

CYCLOOXYGENASE 1; FUROSEMIDE; IBUPROFEN; INDOMETACIN; PARACETAMOL; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR;

ARTICLE; BLEEDING; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; CLINICAL TRIAL (TOPIC); DIGESTIVE SYSTEM PERFORATION; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; HYPONATREMIA; INTESTINE PERFORATION; KIDNEY FAILURE; LIVER TOXICITY; LOADING DRUG DOSE; META ANALYSIS (TOPIC); NONHUMAN; OLIGURIA; PATENT DUCTUS ARTERIOSUS; PERSISTENT PULMONARY HYPERTENSION; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; DUCTUS ARTERIOSUS, PATENT; FEMALE; INFANT; NEWBORN; PREGNANCY;

ACETAMINOPHEN; CYCLOOXYGENASE INHIBITORS; DUCTUS ARTERIOSUS, PATENT; FEMALE; HUMANS; IBUPROFEN; INDOMETHACIN; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; PREGNANCY;

EID: 84930509553     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574886309999141030142847     Document Type: Article

References (79)

1. Mouzinho AI, Rosenfeld CR, Risser R. Symptomatic patent ductus arteriosus in very-low-birth-weight infants: 1987-1989. Early Hum Dev 1991; 27: 65-77.
2. Reller MD, Rice MJ, McDonald RW. Review of studies evaluating ductal patency in the premature infant. J Pediatr 1993; 122: 59-62.
3. Hermes-De Santis ER, Clyman RI. Patent ductus arteriosus: pathophysiology and management. J Perinatol 2006; 26:14-8.
4. Van Overmeire B, Chemtob S. The pharmacological closure of the patent ductus arteriosus. Semin Fetal Neonatal Med 2005; 10: 177-84.
5. Clyman RI. Mechanisms regulating the Ductus Arteriosus. Biol Neonate 2006; 89: 330-5.
6. Graham GG, Davies MJ, Day RO, Mohamudally A, Scott KF. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology 2013; 21: 201-32.
7. Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 2010; CD000174.
8. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2010: CD003481.
9. Demirel G, Erdeve O, Dilmen U. Pharmacological management of PDA: oral vs intravenous medications. Curr Clin Pharmacol 2012; 7: 263-70.
10. Gokmen T, Erdeve O, Altug N, Oguz SS, Uras N, Dilmen U. Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus. J Pediatr 2011; 158: 549-54.
11. Erdeve O, Yurttutan S, Altug N, et al. Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomized controlled trial in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2012; 97: 279-83.
12. Clyman RI, Couto J, Murphy GM. Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all? Semin Perinatol 2012; 36: 123-9.
13. Erdeve O, Sarici SU, Sari E, Gok F. Oral ibuprofen-induced acute renal failure in a preterm infant. Pediatr Nephrol 2008; 23: 1565-7.
14. Anderson BJ. Paracetamol (Acetaminophen): mechanisms of action. Paediatr Anaesth 2008; 18: 915-21.
15. Green K, Drvota V, Vesterqvist O. Pronounced reduction of in vivo prostacyclin synthesis in humans by paracetamol. Prostaglandins 1989; 37: 311-5.
16. Lucas R, Warner TD, Vojnovic I, Mitchell JA. Cellular mechanisms of acetaminophen: role of cyclo-oxygenase. FASEB J 2005; 19: 635-7.
17. Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics 2011; 128: 1618-21.
18. Oncel MY, Yurttutan S, Uras N, et al. An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants. Arch Dis Child Fetal Neonatal Ed 2013; 98: F94.
19. Oncel MY, Yurttutan S, Degirmencioglu H, et al. Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birthweight infants. Neonatology 2013; 103: 166-9.
20. Yurttutan S, Oncel MY, Arayici S, et al. A different first choice drug in the medical management of patent ductus arteriosus: Oral paracetamol. J Matern Fetal Neonatal Med 2013; 26: 825-7.
21. Oncel MY, Yurttutan S, Erdeve O, et al. Oral Paracetamol versus Oral Ibuprofen in the Management of Patent Ductus Arteriosus in Preterm Infants: A Randomized Controlled Trial. J Pediatr 2014; 164: 510-4.
22. Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 1983; 102: 895-906.
23. Fowlie PW, Davis PG. Prophylactic indomethacin for preterm infants: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2003; 88: F464-466.
24. Alfaleh K, Smyth JA, Roberts RS, et al. Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms. Pediatrics 2008; 121: e233-8.
25. Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001; 344: 1966-72.
26. Dani C, Bertini G, Pezzati M, et al. Intra Ventricular Ibuprofen Study Group. Prophylactic ibuprofen for the prevention of intraventricular hemorrhage among preterm infants: A multicenter, randomized study. Pediatrics 2005; 115: 1529-35.
27. Little DC, Pratt TC, Blalock SE, Krauss DR, Cooney DR, Custer MD. Patent ductus arteriosus in micropreemies and full-term infants: the relative merits of surgical ligation versus indomethacin treatment. J Ped Sur 2003; 38: 492-6.
28. Pacifici GM. Clinical pharmacology of indomethacin in preterm infants: implications in patent ductus arteriosus closure. Paediatric Drugs 2013; 15: 363-76.
29. Mosca F, Bray M, Lattanzio M, et al. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr 1997; 131: 549-54.
30. McCormick DC, Edwards AD, Brown GC, et al. Effect of indomethacin on cerebral oxidized cytochrome oxidase in preterm infants. Pediatr Res 1993; 33: 603-8.
31. Van Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000; 343: 674-81.
32. Pezzati M, Vangi V, Biagiotti R, et al. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 1999; 135: 733-8.
33. Van Bel F, Van Zoeren D, Schipper J, Guit GL, Baan J. Effect of indomethacin on superior mesenteric artery blood flow velocity in preterm infants. J Pediatr 1990; 116: 965-70.
34. Fanos V, Benini D, Verlato G, Errico G, Cuzzolin L. Efficacy and renal tolerability of ibuprofen vs indomethacin in preterm infants with patent ductus arteriosus. Fundam Clin Pharmacol 2005; 19: 187-93.
35. Yeh TF, Wilks A, Singh J, Betkerur M, Lilien L, Pildes RS. Furosemide prevents the renal side effects of indomethacin therapy in premature infants with patent ductus arteriosus. J Pediatr 1982; 101: 433-7.
36. Romagnoli C, Zecca E, Papacci P, et al. Furosemide does not prevent indomethacin-induced renal side effects in preterm infants. Clin Pharmacol Ther 1997; 62: 181-6.
37. Reyes JL, Aldana I, Barbier O, Parrales AA, Melendez E. Indomethacin decreases furosemide-induced natriuresis and diuresis on the neonatal kidney. Pediatr Nephrol 2006; 21: 1690-7.
38. Fujii AM, Brown E, Mirochnick M, O’Brien S, Kaufman G. Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus. J Perinatol 2002; 22: 535-40.
39. Sharma R, Hudak ML, Tepas JJ 3rd, et al. Prenatal or postnatal indomethacin exposure and neonatal gut injury associated with isolated intestinal perforation and necrotizing enterocolitis. J Perinatol 2010; 30: 786-93.
40. Hammerman C, Shchors I, Jacobson S, et al. Ibuprofen versus continuous indomethacin in premature neonates with patent ductus arteriosus: is the difference in the mode of administration? Pediatr Res 2008; 64: 291-7.
41. Coombs RC, Morgan ME, Durbin GM, Booth IW, McNeish AS. Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin. Arch Dis Child 1990; 65: 1067-71.
42. Corazza MS, Davis RF, Merritt TA, Bejar R, Cvetnic W. Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus. J Pediatr 1984; 105: 292-6.
43. Romagnoli C, De Carolis MP, Papacci P, et al. Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates. Clin Pharmacol Ther 2000; 67: 676-83.
44. Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubaltelli FF. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 1999; 135: 733-8.
45. Aranda JV, Varvarigou A, Beharry K, et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatr 1997; 86: 289-93.
46. Desfrere L, Zohar S, Morville P, et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Therap 2005; 30: 121-32.
47. Dani C, Vangi V, Bertini G, et al. High-dose ibuprofen for patent ductus arteriosus in extremely preterm infants: a randomized controlled study. Clin Pharmacol Ther 2012; 91: 590-6.
48. Meißner U, Chakrabarty R, Topf HG, Rascher W, Schroth M. Improved closure of patent ductus arteriosus with high doses of ibuprofen. Pediatr Cardiol 2012; 33: 586-90.
49. Yurttutan S, Erdeve O, Oncel MY, Ozdemir R, Dilmen U. The relationship between trough drug concentrations and ductal closure in preterm infants treated with three-dose-oral ibuprofen. J Matern Fetal Neonatal Med 2013; 26: 1306-10.
50. Bersani I, De Carolis MP, Lacerenza S, et al. Is the prophylaxis of patent ductus arteriosus useful in extremely premature infants? Turk J Pediatr 2011; 53: 187-193.
51. Ohlsson A, Shah SS. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2011: CD004213.
52. Kanmaz G, Erdeve O, Canpolat FE, et al. Serum ibuprofen levels of extremely preterm infants treated prophylactically with oral ibuprofen to prevent patent ductus arteriosus. Eur J Clin Pharmacol 2013; 69: 1075-81.
53. Neumann R, Schulzke SM, Buhrer C. Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. Neonatology 2012; 102: 9-15.
54. Peng S, Duggan A. Gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs. Exp Opin Drug Saf 2005; 4: 157-69.
55. Tatli MM, Kumral A, Duman N, Demir K, Gurcu O, Ozkan H. Spontaneous intestinal perforation after oral ibuprofen treatment of patent ductus arteriosus in two very low-birthweight infants. Acta Paediatr 2004; 93: 999-1001.
56. Guzoglu N, Sari FN, Ozdemir R, et al. Renal and mesenteric tissue oxygenation in preterm infants treated with oral ibuprofen. J Matern Fetal Neonatal Med 2014; 27: 197-203.
57. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2013; 4: CD003481.
58. Gournay V, Roze JC, Kuster A, et al. Prophylactic ibuprofen versus placebo in very premature infants: a randomised, double blind, placebo-controlled trial. Lancet 2004; 364: 1939-44.
59. Dani C, Bertini G, Reali MF, et al. Prophylaxis of patent ductus arteriosus with ibuprofen in preterm infants. Acta Paediatr 2000; 89: 1369-74.
60. Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: A randomised controlled trial. Eur J Pediatr 2002; 161: 202-7.
61. Ahlfors CE. Effect of ibuprofen on bilirubin-albumin binding. J Pediatr 2004; 144: 386-8.
62. Cooper-Peel C, Brodersen R, Robertson A. Does ibuprofen affect bilirubin-albumin binding in newborn infant serum? Pharmacol Toxicol 1996; 79: 297-9.
63. Zecca E, Romagnoli C, De Carolis MP, et al. Does Ibuprofen increase neonatal hyperbilirubinemia? Pediatrics 2009; 124: 480-4.
64. Gournay V, Savagner C, Thiriez G, Kuster A, Rozé JC. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet 2002; 359: 1486-8.
65. Rheinlaender C, Helfenstein D, Pees C, et al. Neurodevelopmental outcome after COX inhibitor treatment for patent ductus arteriosus. Early Hum Dev 2010; 86: 87-92.
66. Loeliger M, Shields A, McCurnin D, et al. Ibuprofen treatment for closure of patent ductus arteriosus is not associated with increased risk of neuropathology. Pediatr Res 2010; 68: 298-302.
67. Keady S, Grosso A. Ibuprofen in the management of neonatal Patent Ductus Arteriosus. Intensive Crit Care Nursing 2005; 21: 56-8.
68. Green K, Drvota V, Vesterqvist O. Pronouncedreduction of in vitro prostacyclin synthesis in humans by acetaminophen (paracetamol). Prostaglandins 1989; 37: 311-5.
69. Dang D, Wang D, Zhang C, Zhou W, Zhou Q, Wu H. Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS One 2013; 8: e77888.
70. Tekgunduz KS, Ceviz N, Demirelli Y, et al. Intravenous paracetamol for patent ductus arteriosus in premature infants -a lower dose is also effective. Neonatology 2013; 104: 6-7.
71. Alan S, Kahvecioglu D, Erdeve O, Atasay B, Arsan S. Is paracetamol a useful treatment for ibuprofen-resistant patent ductus arteriosus? Neonatology 2013; 104: 168-9.
72. Dart RC, Rumack BH. Intravenous acetaminophen in the United States: iatrogenic dosing errors. Pediatrics 2012; 129: 349-53.
73. Nevin DG, Shung J. Intravenous paracetamol overdose in a preterm infant during anesthesia. Paediatr Anaesth 2010; 20: 105-7.
74. Isbister GK, Bucens IK, Whyte IM. Paracetamol overdose in a preterm neonate. Arch Dis Child Fetal Neonatal Ed 2001; 85: F70-2.
75. Porta R, Sánchez L, Nicolás M, García C, Martínez M. Lack of toxicity after paracetamol overdose in a extremely preterm neonate. Eur J Clin Pharmacol 2012; 68: 901-2.
76. Anderson BJ, Allegaert K. Intravenous neonatal paracetamol dosing: the magic of 10 days. Paediatr Anaesth 2009; 19: 289-95.
77. Palmer GM, Atkins M, Anderson BJ, et al. I.V. acetaminophen pharmacokinetics in neonates after multiple doses. Br J Anaesth 2008; 101: 523-30.
78. Beringer RM, Thompson JP, Parry S, Stoddart PA. Intravenous paracetamol overdose: two case reports and a change to national treatment guidelines. Arch Dis Child 2011; 96: 307-8.
79. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB. Case records of the Massachusetts General Hospital: laboratory values. N Engl J Med 2004; 351: 1548-63.